ctDNA and Immune Signals Reveal Who Benefits Most from Metastasis-Directed Radiation
The Phase II EXTEND trial found that adding metastasis-directed radiation therapy to standard systemic treatment significantly improved progression-free surviva...
The Phase II EXTEND trial found that adding metastasis-directed radiation therapy to standard systemic treatment significantly improved progression-free survival in oligometastatic cancer, while ctDNA and immune profiling analyses revealed biomarkers that may help identify patients most likely to benefit. The post ctDNA and Immune Signals Reveal Who Benefits Most from Metastasis-Directed Radiation appeared first on Inside Precision Medicine .